Supernus Pharmaceuticals, Inc. (SUPN) Q4 2014 Earnings Results

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.30%

Supernus Pharmaceuticals reported a significant EPS beat, which drove a slight increase in the stock price by 0.30%. The strong EPS performance indicates effective cost management or improved profitability. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.08	N/A	+250.94%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their focus on strategic growth. They did not provide specific guidance for the future.

We are pleased with our performance this quarter, particularly in EPS.

While we did not provide guidance, we are focused on our strategic initiatives.

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.30%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.30%

Key numbers

Management commentary